N/A
N=35
Plasma Protein Binding Characteristics of Voriconazole
Focus of the Study:Protein Binding Characteristics of Voriconazole.
Bottom Line
View on ClinicalTrials.gov: NCT01812473 ↗Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Feb 2015
Primary outcome: Primary: Differences in Overall Protein Binding in the Presence of Different Plasma Albumin Concentrations. — 49.1; 49.6 % of plasma protein binding
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Blood sampling (Other)
- Age
- Pediatric, Adult, Older Adult · 2+ yrs
- Sex
- All
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Primary completion
- Jun 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Differences in Overall Protein Binding in the Presence of Different Plasma Albumin Concentrations. |
49.1; 49.6 | — |
Summary
The purpose of this study is to investigate the influence of hypoalbuminemia on the protein binding characteristics of the antifungal drug voriconazole in ICU patients.
Eligibility Criteria
Inclusion Criteria
- treated with voriconazole
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT01812473). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.